Online inquiry

IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ855MR)

This product GTTS-WQ855MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PRLR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000949.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5618
UniProt ID P16471
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ855MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5706MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ14395MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ15448MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ12441MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ12162MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-009
GTTS-WQ10885MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ7668MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN3013
GTTS-WQ8321MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HN-66000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW